The use of small molecule inhibitors targeting HDAC1 or EZH2 activity rescued expression of RUNX2 with its downstream targets and enhanced osteogenic differentiation of MM‐pretreated murine MC3T3‐E1 preOB cells and patient‐derived MM‐BMSCs15 (Fig. 1). Here, RUNX2 is linked to Miyoshi myopathy.